Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Analysis of ASK crystal structures as well
2025-02-07

Analysis of ASK1 crystal structures as well as an investigation of how Cy3-UTP incorporation in RNA 4 might bind were undertaken to understand opportunities for engaging Gln756. To this end a docking model derived from PDB 3VW622 was used to predict the binding mode of amide 4 in the ASK1 active si
-
Since the beginning of s
2025-02-07

Since the beginning of 1990s, more than 17,000 papers about physiological relevance of antioxidants have been published according to data from web of science. Based on the available literature, it seems that assessing the antioxidant potential of food by means of in vitro assays or solely epidemiolo
-
br Conclusions br Funding This
2025-02-07

Conclusions Funding This work was supported by a Finnish government subsidy for health science research [grant numbers TYH2012141, TYH 2013218, and TYH 2014216]; the SSAC Foundation [grant numbers SLS-504141 and SLS-693781]; and the Paulo Foundation. The funding sources had no involvement in s
-
br Eprosartan The AT R
2025-02-07

Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential ibotenic acid and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events,
-
Furthermore a recently published network
2025-02-07

Furthermore, a recently published network meta-analysis including 30 trials in patients with hypertension and diabetes demonstrated that ARBs have efficacy similar to that of ACEIs for all-cause and cardiovascular mortality (HR 0.95, 95% CI 0.73 to 1.30 and HR 1.23, 95% CI 0.64 to 2.78, respectively
-
br Introduction AMP activated protein kinase AMPK has been f
2025-02-07

Introduction AMP-activated protein kinase (AMPK) has been found to be a key character against cardiovascular diseases and cellular stress. When activated by certain stress, AMPK regulates sugars and fatty acids that are good or detrimental to the heart. For example, targeting AMPK phosphorylation
-
All desired compounds with a
2025-02-07

All desired compounds with a carboxylic Zaragozic Acid A substituent at N1 position of the quinoxalinone scaffold and a variety of aromatic substituents at C3 position were obtained by the syntheses starting from methoxy-substituted 3-chloro-quinoxalin-2(1)-ones () prepared as previously. As shown
-
In conclusion we have shown that
2025-02-06

In conclusion, we have shown that mGlu7 receptors negatively regulate α1-adrenergic receptor signalling in heterologous expression systems, x04 tissue and living animals. This interaction might represent a protective mechanism aimed at restraining an excessive activation of noradrenergic transmissi
-
Introduction Adenosine kinase ADK ATP adenosine phosphotrans
2025-02-06

Introduction Adenosine kinase (ADK; ATP: adenosine 5′-phosphotransferase, EC 2.7.1.20), is isolated from yeast cells by Kornberg for the first time in 1951 [1]. ADK belongs to the ribokinase protein family and is one of the most abundant nucleoside kinases in mammalian tissues [2,3]. As the first i
-
Interestingly a homolog of C elegans acr is present
2025-02-06

Interestingly, a homolog of C. elegans acr-23 is present in the A. suum smad inhibitor (Jex et al., 2011). However, A. suum is not susceptible to monepantel treatment in vivo (Tritten et al., 2011). Our research seeks to advance knowledge on the mode of action of monepantel on nAChRs from Clade III
-
Bioactive saponin The authors thank Dr J Aoki University of
2025-02-06

The authors thank Dr. J. Aoki, University of Tokyo, for kindly providing 5E5-ATX antibody. This work was supported by a grant from the Deutsche Forschungsgemeinschaft to A.E.K. (KR4391/1-1), research grants “Primary sclerosing cholangitis” from the Deutsche Crohn-Colitis-Vereinigung and the Norwegia
-
Since innate immune responses represent the
2025-02-06

Since innate immune responses represent the first defense against incoming infectious microorganisms, they are particularly engaged during the early stages of viral infections. Many innate defense mechanisms rely on the engagement of pattern recognition receptors (PRRs) which are conserved, germ lin
-
In the mammalian brain synapse
2025-02-06

In the mammalian brain, synapse formation is followed by a period of synapse refinement, and autophagy has been shown to play an important role in this process. For example, Tang and colleagues found that autophagy is required for the developmental pruning of dendritic spines, and that this pruning
-
VPS34-IN1 br The future of cancer
2025-02-06

The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor VPS34-IN1 suggests that
-
Aurora A or B selective and pan aurora inhibitors
2025-02-06

Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas
16170 records 32/1078 page Previous Next First page 上5页 3132333435 下5页 Last page